<DOC>
	<DOCNO>NCT02186080</DOCNO>
	<brief_summary>This exploratory study metabolic endotoxemia associate type 2 diabetes . The investigator measure systemic endotoxin level lipid level ingestion high fat diet evaluate effect gemigliptin , DPP-4 inhibitor , metabolic endotoxemia lipemia induce high fat diet .</brief_summary>
	<brief_title>Effect Gemigliptin Metabolic Endotoxemia Lipemia</brief_title>
	<detailed_description>Study subject allocate either gemigliptin placebo . After 4 week treatment 2 week wash period , subject switch opposite arm . The subject test oral fat tolerance test adipose tissue needle biopsy ( subject agree participate donate adipose tissue ) 3 time point : start 1st treatment , end 1st treatment end 2nd treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Endotoxemia</mesh_term>
	<criteria>Age 20 75 At least 6 month diagnosis type 2 diabetes Current diabetes treatment : life style modification and/or metformin and/or sulfornylurea No change diabetes treatment ( drug number dossage ) recent 3 month HbA1c 6.5 % 10 % Recent cardiovascular event 6 month Concurrent use statin fibrate ezetimibe Renal failure , chronic liver disease Pregnancy lactation Use DPP4 inhibitor GLP1 analogue recent 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>metabolic endotoxemia</keyword>
	<keyword>gemigliptin</keyword>
	<keyword>DPP-4 inhibitor</keyword>
</DOC>